Advertisement
Skip to Content

Coloplast A/S ADR CLPBY Stock Quote

| Rating as of

PINX: CLPBY

Last close prices updated as of Mar 23, 2023, 3:49 PM EST | USD
  • Last Close 12.18
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Investment Style Large Growth
  • Day Range 12.17  –  12.36
  • Year Range 9.58  –  16.00
  • Market Cap 25.8590 Bil
  • Volume / Avg 33,082.0 /  65,516.8
  • Price / Sales 7.61
  • Price / Book 30.27
  • Forward Div Yield 2.32%
  • Trailing Div Yield 2.32%

Morningstar‘s Stock Analysis CLPBY

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Coloplast Introduces Next-Generation Catheter; No Change to Our Fair Value Estimate

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie Wang |

Narrow-moat Coloplast kicked off its new fiscal year in strong fashion, despite diminishing ripple effects from the pandemic, and we’re leaving our fair value estimate unchanged. Quarterly organic revenue growth of 7% year over year was closer to what we’d consider typical for the firm. In particular, ostomy and continence care were up 8% and 7%, respectively. The last lingering effects of COVID-19 showed up in softness in China as the country navigated the rise of the omicron variant and shortages of input materials, especially for silicone products, which have hindered the continence care and wound care business. We expect these two dynamics will be ironed out over the next quarter or two.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CLPBY

Company Profile CLPBY

Business Description

Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy-care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and wound-care markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

Contact
Holtedam 1-3
Humlebaek, DK-3050, DNK
Industry Medical Instruments & Supplies
Employees 14,685

Related Articles CLPBY

FAQs for Coloplast A/S ADR Stock

No. CLPBY does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

CLPBY’s market cap is 25.86 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

CLPBY’s stock style is Large Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

CLPBY’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare CLPBY’s historical performance against its industry peers and the overall market.